上海润达医疗科技股份有限公司 独立董事工作制度 上海润达医疗科技股份有限公司 独立董事工作制度 第二章 独立董事的任职条件 第四条 公司独立董事占董事会成员比例不得低于三分之一，且至少包括 一名会计专业人士。以会计专业人士身份被提名为独立董事候选人的，应具备较 丰富的会计专业知识和经验，并至少符合下列条件之一： （一）具有注册会计师执业资格； （二）具有会计、审计或者财务管理专业的高级职称、副教授及以上职称或 者博士学位； 上海润达医疗科技股份有限公司 独立董事工作制度 （二〇二五年八月） 第一章 总 则 第一条 为进一步完善上海润达医疗科技股份有限公司（以下简称"公司"） 法人治理结构，规范独立董事行为，充分发挥独立董事在公司治理中的作用，保 障全体股东特别是中小股东的利益，根据《中华人民共和国公司法》、《上市公 司独立董事管理办法》、《上市公司治理准则》、《上海证券交易所上市公司自 律监管指引第 1 号——规范运作》等相关规定和《上海润达医疗科技股份有限公 司章程》（以下简称"《公司章程》"），制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或 ...

General Principles - The rules are established to standardize the behavior of listed companies, ensure the legal exercise of shareholder rights, and protect the legitimate rights and interests of all shareholders [1][2] - The company must strictly follow laws, regulations, and its articles of association when convening shareholder meetings [1][2] Types of Shareholder Meetings - The company holds an annual shareholder meeting once a year within six months after the end of the previous fiscal year, while temporary meetings are held as needed [2][3] - If a temporary meeting cannot be convened within the specified time, the company must report to the Shanghai Securities Regulatory Bureau and the Shanghai Stock Exchange [2] Legal Opinions and Compliance - The company must hire a lawyer to provide legal opinions on the legality of the meeting's procedures, the qualifications of attendees, and the validity of voting results [2][3] Convening Shareholder Meetings - The board of directors is responsible for convening shareholder meetings within the specified time frame [3][4] - Independent directors can propose temporary meetings, and the board must respond within ten days [3][4] Proposals and Notifications - Proposals must fall within the scope of the shareholder meeting's authority and be submitted in writing at least ten days before the meeting [6][7] - Notifications for annual meetings must be sent at least twenty days in advance, while temporary meetings require a fifteen-day notice [6][7] Meeting Procedures - Shareholder meetings must be held at the company's registered address or a location specified in the meeting notice [8][9] - All shareholders or their proxies have the right to attend the meeting, and each share carries one vote [9][10] Voting and Resolutions - Resolutions can be ordinary or special, requiring a majority or two-thirds majority of the voting rights present, respectively [12][13] - Related shareholders must abstain from voting on matters that affect their interests [13][14] Record Keeping and Disclosure - Meeting records must be maintained for at least ten years and include details such as meeting time, location, and voting results [11][12] - Resolutions must be announced promptly, including details on attendance and voting results [44][45] Legal Compliance and Amendments - The rules must comply with national laws and regulations, and any inconsistencies will be resolved in favor of the law [19] - The board of directors is responsible for revising and interpreting these rules [19]

Core Points - The company is named Shanghai Runda Medical Technology Co., Ltd. and was established as a joint-stock company in accordance with Chinese laws [2][3] - The registered capital of the company is RMB 579.534079 million [2] - The company was approved by the China Securities Regulatory Commission for its initial public offering of 23.6 million shares on May 8, 2015, and was listed on the Shanghai Stock Exchange on May 27, 2015 [3] Company Structure - The company is a permanent joint-stock company, with the chairman serving as the legal representative [2][3] - The company has established a party organization in accordance with the regulations of the Communist Party of China, which plays a leading role in guiding the company's direction and ensuring implementation [3] Business Objectives and Scope - The company's business objective is to be market-oriented and service-focused, aiming to achieve satisfactory economic benefits for the company and its shareholders through standardized and professional operations [5] - The business scope includes technology services, medical device sales, software development, and investment activities, among others [5] Share Issuance and Capital Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued by the company is 579.534079 million, all of which are ordinary shares [7] - The company is prohibited from providing financial assistance for others to acquire its shares, except under specific circumstances approved by the shareholders' meeting [7] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and information access, and they are obligated to comply with laws and the company's articles of association [12][41] - The company maintains a shareholder register based on records from the securities registration and settlement institution [12] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [50][51] - Shareholder proposals must be submitted in writing and can be made by shareholders holding at least 1% of the company's shares [58] Decision-Making and Voting - Resolutions at shareholder meetings can be ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring a two-thirds majority [80][81]

Core Points - The document outlines the rules for the board of directors of Shanghai RunDa Medical Technology Co., Ltd, aiming to standardize decision-making processes and improve operational efficiency [1][2]. Group 1: General Principles - The board of directors is established in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. - The board is accountable to the shareholders' meeting and is composed of eleven directors, including four independent directors and one employee representative [1][2]. Group 2: Board Authority and Responsibilities - The board has the authority to convene shareholder meetings, execute resolutions, and decide on business plans and investment proposals [2][3]. - It is responsible for formulating profit distribution plans, capital changes, and major acquisition strategies [2][3]. Group 3: Meeting Procedures - Board meetings can be regular or temporary, with at least one regular meeting held in each half of the year [4][5]. - The chairman of the board is responsible for convening and presiding over meetings, while the vice-chairman assists in these duties [4][6]. Group 4: Voting and Decision-Making - Decisions require a majority vote from attending directors, and specific procedures are in place for handling conflicts of interest [12][14]. - The board must adhere to the authority granted by the shareholders' meeting and the company's articles of association when making decisions [14][30]. Group 5: Documentation and Record-Keeping - Meeting records must include details such as the time, location, attendees, and voting results, and these records are to be maintained for ten years [33][36]. - The board secretary is responsible for ensuring that all documentation is properly archived and that confidentiality is maintained until official announcements are made [36][39].

一、关于取消监事会的情况 为进一步规范公司运作，完善公司治理，根据《中华人民共和国公司法》《上 市公司章程指引》相关法律、法规和规范性文件的最新规定，结合公司实际情况， 公司将取消监事会，监事会的职权由董事会审计委员会行使。公司《监事会议事 规则》等监事会相关制度相应废止。 本议案尚需提交公司股东大会审议，在公司股东大会审议通过取消监事会 事项之前，公司第五届监事会仍将严格按照有关法律、法规和《上海润达医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的规定继续履行监督职能， 维护公司和全体股东利益。 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-045 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于取消监事会暨修订《公司章程》及部分制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海润达医疗科技股份有限公司（以下简称"公司"）于2025年8月26日召开 第五届董事会第二十四次会议，审 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-044 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于增加 2025 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因公司业务发展的需要，依据实际情况，增加与关联方2025年度日常关 联交易预计的金额。 二、本次增加日常关联交易的情况（单位：人民币万元、不含税） 因业务发展需要，公司依据实际情况，拟增加与下述关联方在2025年度日常 关联交易预计的金额，具体如下： | 关联交易 | 关联人 | 原 2025 | 年度 | 本次增加 | 增加后 2025 | 年 | 差异 | | --- | --- | --- | --- | --- | --- | --- | --- | | 类别 | | 预计金额 | | 预计金额 | 度预计金额 | | 原因 | | 向关联方 采购商品 | 上海通用润达医疗技术 有限公司 | ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-043 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 2025年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金的数额、资金到位情况 根据公司2019年2月 27日召开的第三届董事会第二十六次会议及公司2019 年 3 月 18 日召开的 2019 年第一次临时股东大会决议，并经中国证券监督管理委 员会"证监许可[2020]586 号"《关于核准上海润达医疗科技股份有限公司公开发 行可转换公司债券的批复》核准，上海润达医疗科技股份有限公司（以下简称"公 司"）向社会公开发行可转换为公司 A 股股票的可转换公司债券，债券票面金额 为人民币 100.00 元，按票面金额发行，发行数量 5,500,000 张，期限 6 年，募集 资金总额 550,000,000.00 元，扣除发行费用 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-046 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于续聘公司 2025 年度会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2024 年 12 月 31 日合伙人数量：68 人； （一）机构信息 1、基本信息 机构名称：众华会计师事务所（特殊普通合伙）（以下简称"众华"）； 成立日期：2013 年 12 月 2 日； 组织形式：特殊普通合伙； 注册地址：上海市嘉定工业区叶城路 1630 号 5 幢 1088 室； 重要内容提示： 拟续聘的会计师事务所名称：众华会计师事务所（特殊普通合伙） 一、拟续聘会计师事务所的基本情况 首席合伙人：陆士敏； 截至 2024 年 12 月 31 日注册会计师人数：359 人，其中：签署过证券服务 业务审计报告的注册会计师人数：180 人; 2024 年度经审计的收入总额：56,893.21 万元； ...

上海润达医疗科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-047 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 召开的日期时间：2025 年 9 月 12 日 13 点 30 分 召开地点：上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 12 日 至2025 年 9 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-042 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届监事会第十七次 会议通知于 2025 年 8 月 15 日以邮件形式发出，会议于 2025 年 8 月 26 日（星期 二）14:00-15:00 在上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼公司会议室以现 场的方式召开。会议应到监事 3 人，实到监事 3 人，公司董事会秘书张诚栩先生 列席了会议。会议由公司监事会主席严晨女士主持。 本次监事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 二、监事会会议审议情况 （一）审议通过了《关于审议公司202 ...